Wen-Xuan Liu

Wen-Xuan Liu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Immunology Letters
Verified
Journal Article
Closed access
HLHui Li
Hui Li
HCHai-Ying Chen
Hai-Ying Chen
WLWen-Xuan Liu
Wen-Xuan Liu
XJXian-Xian Jia
Xian-Xian Jia
JZJing-Ge Zhang
Jing-Ge Zhang
CBCong Bin
Cong Bin

1 January 2023 in Oncology Research
Verified
Journal Article
Open access
PDF file
XSXinrui Shi
Xinrui Shi
XGXia Gao
Xia Gao
WLWencong Liu
Wencong Liu
XTXuejiao Tang
Xuejiao Tang
JLJiayi Liu
Jiayi Liu
WLWen-Xuan Liu
Wen-Xuan Liu
Hepatocellular carcinoma (HCC) is the most common fatal cancer worldwide, patients with HCC have a high mortality rate and poor prognosis. PANoptosis is a novel discovery of programmed cell death associated with cancer development. However, the role of PANoptosis in HCC remains obscure. In this study, we enrolled 274 PANoptosisrelated genes (PANRGs) and screened 8 genes to set up a prognostic model. A previous scoring system calculated PANscore was utilized to quantify the individual risk level of each HCC patient, and the reliability of the prognostic model has been validated in an external cohort. Nomogram constructed with PANscore and clinical characteristics were used to optimize individualized treatment for each patient. Single-cell analysis revealed a PANoptosis model associated with tumor immune cell infiltration, particularly natural killer (NK) cells. Further exploration of hub genes and assessment of the prognostic role of these 4 hub genes in HCC by quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC). In conclusion, we evaluated a PANoptosis-based prognostic model as a potential prognostic biomarker for HCC patients.

5 May 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
HLHong‐Min Luo
Hong‐Min Luo
XWXia Wu
Xia Wu
XXXian Xian
Xian Xian
LWLu‐Yao Wang
Lu‐Yao Wang
LZLiang‐Yu Zhu
Liang‐Yu Zhu
WLWen-Xuan Liu
Wen-Xuan Liu
We had previously demonstrated that the calcitonin gene‐related peptide (CGRP) suppresses the oxidative stress and vascular smooth muscle cell (VSMC) proliferation induced by vascular injury. A recent study also indicated that CGRP protects against the onset and development of angiotensin II (Ang II)‐induced hypertension, vascular hypertrophy and oxidative stress. However, the mechanism behind the effects of CGRP on Ang II‐induced oxidative stress is unclear. CGRP significantly suppressed the level of reactive oxygen species (ROS) generated by NADPH oxidase in Ang II‐induced VSMCs. The Ang II‐stimulated activation of both Src and the downstream transcription factor, STAT3, was abrogated by CGRP. However, the antioxidative effect of CGRP was lost following the expression of constitutively activated Src or STAT3. Pre‐treatment with H‐89 or CGRP8–37 also blocked the CGRP inhibitory effects against Ang II‐induced oxidative stress. Additionally, both in vitro and in vivo analyses show that CGRP treatment inhibited Ang II‐induced VSMC proliferation and hypertrophy, accompanied by a reduction in ROS generation. Collectively, these results demonstrate that CGRP exhibits its antioxidative effect by blocking the Src/STAT3 signalling pathway that is associated with Ang II‐induced VSMC hypertrophy and hyperplasia.

1 September 2021 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
GXGao Xia
Gao Xia
ZLZhang Li
Zhang Li
ZLZhou Lin
Zhou Lin
ZXZheng XuRan
Zheng XuRan
YMYang MengRu
Yang MengRu
WLWen-Xuan Liu
Wen-Xuan Liu